



## Nanocarrier: A Boom or a Bane in the Medical Industry

Govind Arora<sup>1\*</sup>, Kanav Midha<sup>1</sup>, Priyanka Diwan<sup>2</sup>, Simran Marwah<sup>3</sup>, Ankita Sood<sup>1</sup>

<sup>1</sup>Chitkara College of Pharmacy, Punjab, India

<sup>2</sup>IAMR College, Ghaziabad, India

<sup>3</sup>Amity University, Noida, India

\*Corresponding Author: Govind Arora, Chitkara College of Pharmacy, Punjab, India. ORCID : 0000-0001-9481-6868

Received: March 28, 2019; Published: April 09, 2019

### Abstract

Recently, inorganic nanostructures which interface with biological systems have attracted widespread interest in biology and medicine. Nanocarriers are considered to have potential as a novel intravascular advantage for both diagnostic (e.g. imaging) and therapeutic purposes (e.g. drug delivery). Most vital issues for successful nanocarriers include the ability to target specific tissues and cell types and escape from the biological particulate filter known as the reticular endothelial system. Nanocarriers include many types of drug delivery methods for preparation of nanoparticles, nanocrystals, etc. depending upon various factors. The main approach of the nanoparticles has been to alter the pharmacokinetics and pharmacodynamics property of the free drug. Various methods and polymers are used to create a fine and a potent nanoparticle. This review would take you through a short citation of the nanocarrier's classification, characterization, formulation, and their application in the pharmaceutical industry for treating the pathological conditions.

**Keywords:** Nanocarriers; Medicament; Drug Delivery; Pharmaceutical Application


### Introduction

The field of nanotechnology is rapidly growing and includes the development of man-made materials in the 5–200 nanometer size range. This dimension immensely exceeds that of standard organic molecules, but its lower range approaches that of many proteins and biological macromolecules. Nowadays delivering a drug is the most complicated task in today's world. Most difficult challenge is the delivery of the medicament to its appropriate site of action so that it can have the most effective therapeutic effect till its maximum level [1].


The main motive behind targeting of the drug is mainly to reduce the risk–benefit ratio for a specific action. Nanocarrier is one of the most specific and the most effective way of carrying the medicament to a specific area. It is being studied on a very vast platform. Nanocarriers have a very high potency of carrying a medicament to a very specific site and they also have a good pharmacokinetic activity and also a good absorbance value as compared to the normal delivery methods. Nanocarriers show a high surface area to volume ratio. This results in enhancing the hydrophobic

drugs solubility and making them appropriate for the parenteral administration [2,3].

They are not limited to just increase the solubility of the hydrophobic drugs, but they also act over many properties of the drugs like stability of the active pharmaceutical ingredient. Nanocarriers are now widely being used for delivering the drug over central nervous system of the body as it helps to decrease the size of the particle which results in good binding over the site of action and acts as a good carrier for the drug. An ideal nanocarrier should have properties or either we can say abilities like extending the blood circulation, making active moiety to bind to its respective site of action, and bypassing bimolecular reactions in the body. They are usually comprised of macromolecular materials with the active principle either dissolved within a polymeric matrix, entrapped inside lipid, encapsulated, or adsorbed onto surfaces of particles. So, they can be classified as mainly two types—nanocapsule and nanospheres. The former are vesicular systems in which drug molecules are enclosed by a membrane, while the latter are a matrix system with the drug molecules dispersed all over as explained in Scheme 1 [4,5].



**Scheme 1:** Diagrammatic representation of nanosphere (A) and nanocapsule (B).



**Scheme 2:** Different type of interaction of the nanocarriers with a specific intracellular cell.

Nanocarriers have a significant factor of properties to be an effective nanocarrier and these properties include: [6]

- It should protect drug from getting degraded before it gets into the systemic circulation
- It should not allow the drug to have a reaction with any of the environmental factor
- It should have high absorption rate for the specific tissue of its site
- It should be capable of controlling the pharmacokinetic profile of the drug and should also show an effective result over the distribution profile
- Should comparatively increase the intercellular penetration.

There are many possible ways to overcome the desired binding of the nanocarrier as it is the most basic necessity of the nanocarrier composition. The bonding can be made more specific by attaching the target-mediated agents such as ligands, as they specifically bind to the surface of the cell. Nanocarriers will recognize target cells and bind with them through ligand–receptor interactions, and bound carriers are internalized before the drug is released inside the cell. Normally, when a targeting agent is used to deliver nanocarriers to cancer cells, it is essential that the agent binds with high selectivity to molecules that are exclusively expressed on the cell surface [7].

There are many types of targeting agents which can be used for the specific targeting of the nanocarriers (Scheme 2). They can be broadly classified as proteins, nucleic acid, and other receptor ligands. Nanocarriers can also be utilized to enhance local drug concentration by transporting the drug within and control-releasing it when bound to the targets. Currently, natural and synthetic polymers, and lipids are usually considered as drug delivery vectors, conjugates, polymeric nanoparticles, lipid-based carriers such as liposomes and micelles, dendrimers, carbon nanotubes, and gold nanoparticles, including nanoshells and nanocages. Clinically approved formulations are listed in Table 1 [8].

S. No	Compound	Commercial Name	Nano carrier	Indication
1	Styrene maleic anhydride-neocarzinostatin	Zinostatin	Polymer-Protein Conjugate	Hepatocircular carcinoma
2	PEG-L-Asparaginase	Onspar	Polymer-Protein Conjugate	Acute lymphocytic leukemia
3	PEG-granulocyte colony-Stimulating factor	Neulasta	Polymer-Protein Conjugate	Prevention of the chemotherapy induced neutropenia
4	Daunorubicin	Dau-noXome	Liposomes	Kaposi sarcoma
5	Doxorubicin	Myocet	Liposomes	Treatment for breast cancer, Kaposi sarcoma, Ovarian cancer.
6	Doxorubicin	Doxil	PEG-Liposomes	Refractory Doxorubicin
7	Vincristine	OncotCS	Liposomes	Relapsed aggressive (NHL)
8	Paclitaxel	Abraxane	Albumin-bound Nanoparticles	Metastasis breast cancer
9	Anti-CD20 Conjugated to iodine-131	Bexxar	Radio-Immunoconjugate	Relapse or refractory (NHL)

**Table 1:** Clinically approved nanoparticle formulations.

## Nanoparticles

Approach of nanoparticle includes small-scale delivery systems like drug-releasing chambers, nanoparticles, micro-fabricated devices, and combining drug delivery to the sensors and implants. The most common small-scale delivery system used nowadays is the nanoparticle drug delivery system. They are being widely used for the purpose of drug delivery to the targeted area and in cosmetic also. Usually the particles under the scale of 100 nm generally form the drug-polymer complexes or make nanoscale shells which mainly work by entrapping the drug in their matrix. The size of these carriers is usually small (from a few tenths to a few hundreds of nanometers) that allow systemic (intravenous) or local (mucosal) administration and enhances their diffusion within the cell. Additionally, current surface functionalization methods can impart nanocarriers with the power to control, at least in part, their pharmacokinetics and biodistribution [9].

The main advantages of using the nanoparticles include [10]:

- The particle size and the surface properties of the nanoparticle can be manipulated easily. This leads to the achievement of the both passive and active drug targeting.
- The control and sustain release can be easily attended during the transportation of the drug in the body.
- It also helps in altering the organ distribution and the clearance of the drug.
- Particle degradation can be controlled over by the selection of the matrix constituent.
- Site-specific targeting can be achieved easily in the formulation of the nanoparticles.
- This system of drug delivery can be utilized for several routes of administration.

In spite of these advantages, nanoparticles have limitations also. For example, their small size and large surface area can cause particle-particle aggregation, which leads to difficulty in making physical handling of nanoparticles in liquid and dry forms. In addition, small particle size and large surface area results in reduced drug loading and burst release. These practical issues have to be overcome before nanoparticles can be used clinically or made commercially available.

## Preparation of Nanoparticles

Nanoparticles can be developed from a variety of materials such as proteins, polysaccharides, and synthetic polymers. The choice of matrix materials relies on many factors that include: [11]

- Size of nanoparticle
- Inherent properties of drug

- Surface characterization
- Degree of bioavailability and biocompatibility
- Drug release profile
- Antigenicity of the product.

Nanoparticles have been developed frequently by three significant methods, namely, dispersion of preformed polymers, polymerization of monomers and ionic gelation or coacervation of hydrophilic polymers [12].


### Dispersion of performed polymer


This technique is commonly prepared in the industry for the formation of the nanoparticles which are biodegradable by nature. These nanoparticles are made through poly (lactic acid), poly (D, l-glycoside), and poly (D, l-lactic-co-glycoside) [12].

### Solvent evaporation method

In this technique, for the formation of the nanoparticle, polymer has to be dissolved in the organic solvent followed by the addition of the surfactant to form oil-in-water emulsion. When the final process is being done and the emulsion is prepared, it is stirred continuously so that the solvent forms the emulsion. One thing to be taken care of is the stirring process that needs to be continuous so that the particle size is small. It further includes the formation of the microspheres with two techniques which are [13]:

- Single emulsion technique, which can be carried forward according to the steps given in Scheme 3.
- Double emulsion technique, that can be followed by the researcher with the steps given in Scheme 4 to carry the process of making the microsphere.





### Solvent diffusion method

The solvent diffusion method is just a modification of the solvent evaporation method, with the two methods sharing many similarities, and it includes the following steps [12]

- Water miscible solvent and organic solvent are prepared to make a final solution.
- Small amount of water immiscible organic solvent is used to make the final product.
- The final addition of the phase creates the formation of the oil phase.
- Interfacial turbulence occurs due to which there is formation of small sized particles.

### Polymerization method

There is a need of increasing particle binding with the specific receptor in the body, especially in case of nanoparticle as it is a very basic and a very important factor. This method mainly works on the same objective. In this method, the nanoparticles mainly bind with the specific polymer so that it interacts with the respective receptor more efficiently. This binding of the nanoparticle can be done through incorporation of the polymer or it can also be done through the absorption process with the nanoparticles. Surfactants are added to attain stability in the process and they also play a very important role in particle size [13].

### Evaluation of nanoparticles

After the formulation, a much important step is the evaluation, since without evaluation, these nanoparticles cannot be used clinically. The first and the basic step is the evaluation of characteristic properties like particle size, zeta potential, etc. The one and only way of finding these properties includes photo collection spectroscopy (PCS). This is the one and only effective method through which we can go for the evaluation for the particle size. Then comes the measurement of the zeta potential measurement of the nanoparticle. It is done through 0.1nM hank's buffer at pH of 7.4 through the apparatus at zeta plus mode.

The transmission electron microscopy is also done for the evaluation of the nanoparticles. In this method, the nanoparticle solution or the sample is fixed with 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer pH 7.4. Then it is prefixed in 1% osmium tetroxide in the same buffer solution for 1 hour. It is then dehydrated in the acetone series and embedded in the epoxy resin. After all this process, the transmission microscopy is done. Particle size study can also be done through one more method that is through scanning electron microscope (SEM) [14-20].

### *In vitro* and *in vivo* studies for nanoparticles

*In vitro* and *in vivo* studies are the need for the hour in the case of evaluation of the nanoparticles. Coming on to the *in vivo* studies which are the basic and the vital studies after the formulation of some or the other nanoparticles formulation. The basic motive behind the *in vivo* studies is to check the drug release studies, uniform drug distribution studies or any other preformulation studies [18].

*In vivo* studies include the dialysis tube studies which are done with the help of an artificial membrane in the presence of the phosphate buffer with pH 7.4 for the formulation but in addition it also includes some models which are to be followed in the case of the *in vivo* studies for the formulation of the nanoparticles. One of the main models is the kinetic model.

In this model, the main motive is to understand the mechanism of the drug and the *in vivo* data is fitted to various kinetic equations like zero order, first order, and second order. Each equation is represented as in Table 2.

S. No	Order	Significance
1	First	Cumulative % release vs. time
2	Second	Log % drug release vs. time
3	Higuchi's model	Cumulative % drug release vs. square root of time.

**Table 2:** Kinetic studies of nanoparticles.

Then after the kinetic model comes the stability studies which are also very important for the nanoparticle formulation. It is done with the help of the phosphate buffer solution (PBS) method at a pH of 6.8. Incubation process is carried out at 5-8°C for a period of 60 days and after the incubation centrifugation is carried out at 1500 rpm for one hour. Followed by the process of centrifugation, filtration is done and samples are taken for UV at 271 nm [15-17].

### Pharmacokinetic action

#### Absorption

Human body gives us a proper clearance mechanism for a rational use of the nanoparticles drug delivery system administration

into the body. Ever since the drug is administered in the body it undergoes the systemic circulation and undergoes the ADME (Absorption, Distribution, Metabolism, and Elimination). The distribution of the medicament is really important for the absorption for the prescribed action of the drug over the body or the desired action of drug in a specific formulation for the body [20].

Other techniques being explored nowadays for the target specific delivery include:

- Altering the size of the nanoparticle carrier
- Surface manipulation for the respective nanoparticle on the bases of its nature of the existence
- It can also be done through the sheathed technique with some or the other compatible polymer.

The most important thing which needs to be considered for the drug delivery is the kinetic payload of the drug which is ignored or neglected during the drug development or we can also say the initial developing stage of the drug, as the fast-kinetic payload movement of the drug can result in the decline of the drug efficacy.

#### Clearance\Excretion

Clearance of any drug is a vital factor for any of the drug being formulated as it should show efficient clearance for the drug in a specific time. The most basic factor which is taken for the clearance activities is the particle size of the drug. As the clearance and the particle size factor are directly proportional to each other, the bigger the particle size, the greater would be the clearance that would be affected by the size. The smaller the particle is, the better behavioral clearance would be shown by the drug [21,22].

#### Toxicity

Toxicity is the major factor during the nanoparticles delivery systems and the probability of nanoparticles to make the system toxic is really high. Thus, the toxicity studies are to be done primarily for the nanoparticle's formulation. The main factor which plays an important role in the toxicology or toxicity studies of the nanoparticles is the size ratio between the nanoparticles and the vascular diameter. As higher ratio values between them can result in the embolization and accumulation of the blood. In some clinical or pathological areas, it may also act as a beneficial factor to treat some chronic diseases like tumors; mainly of the GIT tract [23].

The most common and the most expected side effect which is the main cause of worry most of the times for the patients undergoing the nanoparticles drug delivery treatment is the organ accumulation of the nanoparticles. If this stage arises, the drug or the specific formulation is not considered to be fit for the use and is not processed further for the studies. The reason why the drug is

withdrawn is that the prolong use of the drug can result in stroke and myocardial infarction. Till now, the biggest challenge between with the nanoparticle's toxicity is the toxicity profile. As the striking parallel between the nanoparticles and the ultra-fine particles found in atmospheric condition according to some studies, inhalation of them can cause toxicity and can further cause some severe pathological condition.

#### Cellular targeting mechanism

##### Nanoparticles uptake of the tissue

A succession of various membrane layers presents a complication for therapeutic agents which are trying to target intracellular structures. During this process, compound is lost because of an ineffective partitioning across biological membranes. The degree of partition across a membrane is associated directly to the polarity of a molecule; nonpolar or lipophilic molecules that easily avoid this complication with higher penetration of membrane, generally via diffusion. However, the situation is much more complicated, as a myriad of other cellular processes that directly affect the intracellular concentrations and effectiveness of the therapeutic agent. Inconsistent efficiencies of endocytosis mechanisms, intracellular trafficking, release of the therapeutic agent into the cytoplasm, diffusion and translocation of the therapeutic agent to its susceptible target, and partition into the nucleus or other organelles change the actual activity of the therapeutic agent. Nanoparticles present a remarkable opportunity for eradicating much of this "waste" due to masking of the therapeutic agent from its biological environment; this efficiently regulates the influence of a compound's physical properties on intracellular drug concentrations. Instead, the properties and surface characteristics of the nanoparticle play a crucial role in delivery of compound and resulting intracellular drug concentrations [24,25].

##### Cellular phagocytosis/endocytosis

Receptor-mediated endocytosis presents the potential for even greater selectivity in cellular targeting. The cellular membrane is dotted with a myriad of receptors, which upon extracellular binding to their respective ligands (or to nanoparticles whose surface is functionalized with ligands), transduce a signal to the intracellular space. This signal can initiate a multitude of biochemical pathways; but it may also cause internalization of the ligand and its appended nanoparticle via endocytosis. Caveolin- and clathrin-coated pits offer a demonstration of receptor-mediated endocytosis. Typically, clathrin coats produce a membrane indentation with a radius of curvature as small as approximately 50 nm, and invaginate further upon binding of the ligand. Cross-linking of receptors via ligands attached to nanoparticles causes a more pronounced membrane crater with subsequent enfolding and reunification of the cellular

membrane to develop an endosome. It has been demonstrated that nanoparticle sizes between 25 nm and 50 nm are essential for optimal endocytosis and intracellular localization [26].

### Small scale targeted delivery

The term “small scale” in the heading of this topic tells us the entomb disciplinary and scale-crossing over nature of the field; science, miniaturized scale fabrication, science and medication all combine, each with their own feeling of what is little. Traditional divisions of full scale, microscale, and nanoscale are not really supportive in portraying and looking at medication conveyance strategies. Additionally, the writing does not give a steady qualification between miniaturized scale innovation and nanotechnology. A few creators pick the size of 100 nm as the partitioning line; others stress the idea of the union—“top down” or “base up”. Full-scale and small-scale manufacture is frequently viewed as a best down process: the material is created into its last shape from a bigger piece through the expulsion of undesirable areas by machining or scratching. Base up blend, a term generally used to depict nanoinnovation, alludes to combination dependent on iota by-particle (or atom by-particle) get together of structures. Silicon smaller scale manufacture, for example, the strategies used to create the most recent age of PC processors, is still for the most part a best down process, with a base component size of 130 nm, albeit continuous advances in lithography will before long allow include sizes underneath 100 nm [27].

### Microfabricated devices

Numerous sorts of implantable controlled delivery device are in different phases of creation and clinical assessment. These gadgets have been intended to discharge drugs at different measurements and for both irregular and ceaseless conveyance. They are intended to work for short periods (days) or for expanded periods (~1 year); some can be refilled during use and others are not intended to be refilled. One sort of configuration consolidates numerous fixed compartments, which are opened on request to convey a measurement of a medication. Another method is to utilize microscale pumps and valves that meter conveyance from a bigger scale store. For every one of these methodologies, cost, security, biocompatibility, and long-haul usefulness are, for the most part, being examined. As these gadgets are for the most part made by micromachining, it ought not be hard to include canny control frameworks. For instance, lectin-adjusted mucoadhesive liposomes tie in high numbers to the mass of the digestive tract. Different sorts of polymer particles have likewise been made to target medications to the intestinal divider. This approach has been reached out to little scale gadgets in the state of free-gliding drug conveyance “fixes” that hold fast to the mucosal film in the intestine, protecting the medication from luminal proteolytic chemicals [28].

Despite the fact that it is hard to control the conveyance rate of mixes given orally, regardless of whether in regular plans or in the fresher mucoadhesive gadgets, it has been demonstrated that liposomes containing iron oxide nanoparticles tie with higher partiality to the Peyer's patches in the intestinal divider when controlled alongside an external attractive field. This sort of methodology may give a method for controlling the mean freedom times of particles or gadgets, and subsequently the measure of medication consumed. A more crucial way to deal with *in vivo* tranquilize conveyance would be on-request amalgamation of a coveted atom. This sort of gadget, however more distant from application, has extraordinary adaptability in that therapeutics, (for example, proteins or peptides) could be incorporated as required, either in a downsized rendition of a concoction synthesizer or by “programming” hostage cells with the suitable DNA to create the compound of intrigue. Programmable frameworks for substance union on interest may consolidate propels in micro fluidics. Micro fluidic gadgets have been created for tissue building and medication conveyance. Disregarding the way that it is difficult to control the movement rate of blends given orally, paying little heed to whether in customary plans or in the more breakthrough mucoadhesive contraptions, it has been shown that liposomes containing iron oxide nanoparticles attach with higher affection to the Peyer's patches in the intestinal divider when controlled close by an external appealing field. This kind of system may give a strategy for controlling the mean opportunity times of particles or contraptions, and thusly the proportion of prescription ingested. A more focal approach to manage *in vivo* sedate transport would be on-ask for association of a pined for molecule. This kind of contraption, anyway more removed from application, has wonderful flexibility in that therapeutics, (for instance, proteins or peptides) could be coordinated as required, either in a cut back type of a substance synthesizer or by “programming” prisoner cells with the best possible DNA to make the compound of interest. Programmable systems for manufactured blend on intrigue may meld moves in micro fluidics. Micro fluidic devices have been created for tissue planning and medicine movement [29].

### Chambers

- **Dispersion chambers:** Dispersion chamber holding a freight of medications or cells and fixed with a semi penetrable film have been utilized as research apparatuses for over 70 years. Miniaturized scale and nanofabricated films in these gadgets permit more noteworthy control of the dosage profile and, on account of nanoporous layers, allow the concealment of parts of the safe reaction. Likewise, the small scale created gadgets can incorporate hardware to control or measure the dosage rate or potentially other conditions inside the chamber. While the soonest approaches depended on channel layers with pore sizes of 0.4  $\mu\text{m}$  or bigger; more current work

has prompted gadgets with pore sizes as little as 20 nm; such frameworks are talked about further beneath. Strong medications can be conveyed for expanded periods utilizing dissemination controlled embedded tubes. Not at all like dispersion chambers, which have a substantial layer surface territory contrasted and the store volume for genuinely quick discharge rates, tubes depend on a restricted gap to give a moderate conveyance rate and are normally intended for long haul arrival of very intense medications, with discharge times on the request of years [30].

- **Cell chambers:** *In vivo* cell chambers offer a technique for utilizing isolated states of cells in research and in medication conveyance. Xenografted and hereditarily designed cells can fabricate remedial compounds inside the chamber while the chamber keeps the phones physically separated from whatever is left of the body and its invulnerable framework. Cell chambers have been utilized to create mixes, for example, erythropoietin, insulin and interferon  $\alpha$ . They have likewise been utilized to contain growth cells to invigorate regular malignancy battling component. Albeit such frameworks have been powerful in dividing cells from malicious host cell safe reactions, they regularly have not prohibited humoral insusceptible framework segments, for example, IgG. In this regard, better films (with 100 nm pore measure) that decrease access of some resistant framework segments were a change over the prior gadgets. All the more as of late, micro machined layers with controlled pore sizes of  $\sim 10$  nm have been appeared to reject unwanted safe edifices all the more viably while allowing sensibly quick arrival of the coveted compound from the chamber. Another problem in the improvement of implantable cell chambers concerns the supply of sufficient supplements to the exemplified cells. One way to deal with location this is half breed chambers that supply oxygen by electrolysis of water. Other methodology is to create oxygen by electrolysis and to expel the undesirable protons delivered by particle trade [31].

## Nanoparticles

Nanoparticles area unit is already in use in many areas of drug delivery and cosmetics. Typically, smaller than 100 nm, they are created by forming nanocrystals or drug-polymer complexes or by making nanoscale shells (such as liposomes) that capture drug molecules. Nanoparticles have uncommon properties that may be exploited to boost drug delivery. As a result of their fine size, they're usually concerned by cells wherever larger particles would be eliminated or cleared from the body. tiny molecules, peptides, proteins and nucleic acids are often loaded into nanoparticles that do not seem to be recognized by the system which are often targeted to explicit tissue sorts. Recent ways embody the utilization of poly ethylene glycol (PEG) to extend circulation time moreover because the use of PEG in competition with binding teams to scale back non-specific attachment or uptake. Aerosol delivery may be considered to take particles into the deep tissue of the lungs wherever they're

absorbed rapidly. Optimizing the dimensions and density of the particles enhances delivery potency. Blessings of aerosol delivery embrace eradication of the discomfort and stigma of frequent injections. Recent work has shown that nanoparticles are often included into micron-sized, porous carrier particles for aerosol delivery, joining the convenience of aerosol delivery and therefore the bio-availability of the nanoparticles discharged from the larger particle within the deep respiratory organ tissue [32].

Much effort has gone into producing polymeric nanoparticles and liposomes for the delivery of genes, furthermore as alternative non-infective agent gene delivery strategies like the sequence gun. Artificial vectors gift promising substitutes to infective agent delivery for economic, producing and safety reasons. One example is pH-sensitive nanoparticles that stay together till they need been haunted by a cell, and then, beneath low-pH conditions, quickly disintegrate and unharness their payload. Cationic polymers that are salt and blood serum stable and have bioactive functionalities to boost intracellular trafficking provide enhanced stability and delivery potency. Recent work that has compared libraries of distinctive degradable polymers found many who transfected a lot of with efficiency than typical systems, like poly (ethyleneimine). Alternative work has centered on modifying poly (ethyleneimine) to boost transfection potency and scale back the toxicity. Another approach is to advanced inclusion body deoxyribonucleic acid with stearyl-poly (L-lysine) and LDL. This multiple transfects a lot of with efficiency, with longer period super molecule expression, than naked inclusion body alone Another focus of analysis is that the production of metal and metal oxide nanoparticles with antimicrobial activity. Metal ions are operational for a few time as antimicrobial agents: mercury was used, inefficaciously, against the bubonic plague in Europe, and element compounds were used, a lot of effectively, against pox at the flip of the twentieth century. the utilization of antimicrobial formulations containing zinc, cadmium, zirconium or tin salts mixed with polymers dates back to the sixties. Chemical compound particles containing metal were created within the early nineties and, a lot of recently, there has been abundant work on metal-oxide and silver nanoparticles shaped either from resolution part or in place on a surface. Early work had shown that the efficacy of silver against microorganism depends thereon being each out there and in a very soluble kind. A comparison of a silver salt (silver nitrate) and a silver chelating agent (silver sulfadiazine) unconcealed that they are equally effective and are each considerably simpler than silver ions shaped electrochemically, that are believed to be not significantly bio-available. it's fascinating to notice, however, that there are reports of silver-resistant *Escherichia* infections. Though the antimicrobial agents could also be new, the teachings of antibiotic resistant infections must not be unheeded [33].

## Application of nanoparticles till-date in the industry

### Tumor targeted using nanoparticles delivery system

The principle of exploitation of nanoparticles for tumor targeting is predicated as:

- Nanoparticles are able to deliver a concentrate dose of drug within the neck of the woods of the neoplasm targets via the improved porousness and retention result or active targeting by ligands on the surface of nanoparticles
- Nanoparticles can scale back the exposure of drug towards health tissues by limiting drug distribution to focus on organ.

Verdun., *et al.* incontestable in mice treated with antibiotic incorporated into poly (isohexylcyanoacrylate) nanospheres that increased concentrations of antibiotic manifested within the liver, spleen and lungs than in mice treated with free antibiotic forty seven. Studies show that the compound composition of nanoparticles like sort, property and biodegradation profile of the chemical compound in conjunction with the associated drug's relative molecular mass, its localization within the nanospheres and mode of incorporation technique, sorption or incorporation, have a good effect on the drug distribution pattern *in vivo*. The precise underlying mechanism isn't totally understood however the biodistribution of nanoparticles is fast, at intervals ½ hour to three hours, and it seemingly involves MPS and endocytosis/phagocytosis method. Such propensity of MPS for endocytosis/phagocytosis of nanoparticles presents a chance to appropriately deliver therapeutic agents to those cells. This biodistribution may be of profit for the chemotherapeutical treatment of MPS wealthy organs/tissues localized tumors like hepato-malignant neoplastic disease, internal organ metastasis arising from digestive tube or gynecologic cancers, bronchopulmonary tumors, primitive tumors and metastasis, tiny cell tumors, malignant neoplasm and leukemia. It has been proven that exploitation antibiotic loaded typical nanoparticles was effective against internal organ metastasis model in mice. it absolutely was found there was bigger reduction within the degree of metastasis than once free drug was used. The fundamental mechanism liable for the multiplied therapeutic effectiveness of the formulation was transfer of antibiotic from healthy tissue, acting as a drug reservoir to the malignant tissues fifty. Microscopic anatomy examination showed a substantial addition of nanoparticles within the lysosomal vesicles of Kupffer cells, whereas nanoparticles couldn't be clearly known in tumoral cells fifty. So Kupffer cells, when a vast uptake of nanoparticles by bodily function, were able to induce the discharge of antibiotic, resulting in a gradient of drug concentration, favorable for a chronic diffusion of the free and still active drug towards the neighboring pathological process cells [34].

### Long circulating nanoparticles

To achieve success as a drug delivery system, nanoparticles should be able to target tumors that are localized outside MPS-rich organs. Within the past decade, an excellent deal of labor has been dedicated to producing alleged "stealth" particles or PEGylated nanoparticles, that square measure invisible to macrophages or phagocytes. A significant breakthrough within the field came once the employment of deliquescent polymers (such as polythene glycol, poloxamines, poloxamers, and polysaccharides) to expeditiously coat standard nanoparticle surface created an opposing impact to the uptake by the MPS. These coatings give a dynamic "cloud" of deliquescent and neutral chains at the particle surface that resist plasma proteins. Thus, those coated nanoparticles become invisible to MPS, therefore, stayed within the circulation for an extended amount of your time. Deliquescent polymers will be introduced at the surface in 2 ways in which, either by surface assimilation of surfactants or by use of block or branched copolymers for nanoparticles development. Studies show nanoparticles containing a coat of PEG not solely have a chronic half-life within the blood compartment however even be able to by selection extravasate in pathological sites like tumors or inflamed regions with a leaky vasculature. As a result, such long-circulating nanoparticles have inflated the potential to directly target tumors situated outside MPS-rich regions. The dimensions of the mixture carriers also as their surface characteristics square measure the vital to the biological fate of nanoparticles. A size but a hundred nm and a deliquescent surface square measure essential in achieving the reduction of bodily process reactions and subsequent clearance by macrophages fifty-two. Coating standard nanoparticles with surfactants or PEG to get a long-circulating carrier has currently been used as a typical strategy for drug targeting *in vivo*. Targeting with little ligands seems a lot of seemingly to succeed since they are easier to handle and manufacture. Moreover, it may well be advantageous once the active targeting ligands square measure utilized in collaboration with the long-circulating nanoparticles to maximize the chance of the success in active targeting of nanoparticles [35].

### Nanoparticles for oral delivery of peptides and proteins

Significant advances in biotechnology and organic chemistry have led to the invention of an outsized variety of bioactive molecules and vaccines supported peptides and proteins. polymeric nanoparticles permit encapsulation of bioactive molecules and shield them against protein and hydrolytic degradation. For example, it has been found that endocrine-loaded nanoparticles have preserved insulin activity and made blood sugar decrement in diabetic rats for up to fourteen days following the oral administration. The extent of human mucous membrane extends to 200 times that



of skin. The duct provides a range of physiological and morphological barriers against macromolecule or amide delivery, e.g., (a) chemical change enzymes within the gut lumen like enzyme, enzyme and chymotrypsin; (b) chemical change enzymes at the comb border membrane (endopeptidases); (c) microorganism gut flora; and (d) mucous secretion layer and vegetative cell lining itself. The histologic design of the tissue layer is meant to expeditiously stop uptake of material from the setting. One vital strategy to beat the canal barrier is to deliver the drug in a very mixture carrier system, like nanoparticles, that is capable of increasing the interaction mechanisms of the drug delivery system and therefore the epithelia cells within the gastrointestinal tract [36].

### Nanoparticles of the gene delivery

#### Neuron protection in the ischemic stroke

In recent years, nanoparticulate drug delivery systems have attracted way more attention as safe and effective systems for transporting neurotherapeutic agents across the blood–brain barrier (BBB). This is often thanks to their improved stability and their passive/active targeting properties that enhances drug concentration within the pathological lesion to realize desired therapeutic effects. a close understanding of the pathophysiological changes in anemia brain injury is crucial to the look and application of various therapeutic ways. So, during this review, we have a tendency to concisely the molecular pathological mechanisms of cerebral stroke and also the limitations of current treatments. More importantly, this review provides an outline of this and future applications of nanoparticles (NPs) for the management of ischemic stroke. We have a tendency to mention the sections in line with the various materials used for NPs preparation, since NPs ready from completely different materials have their own blessings and limitations, which could give steerage and helpful data for NPs clinical translation. The general obsessive system of cell death in the human body mainly triggered by the ischemic stroke nitrogen oxide cascade [37].

Cerebral ischemia and reperfusion injury result in harm of brain tissues. Therefore, new post stroke therapies square measure needed to diminish damaging molecular events and cellular death. As a promising therapeutic approach, neuro protection aims not solely at extending survival of neurons after hypoxia and ischemia to extend the therapeutic window, however additionally at causation neurologic repair to boost practical outcomes. However, no current effective medical care is accustomed reverse neural tissue harm when stroke. As an important part in regulation of the equilibrium of the inner setting of the brain, the BBB additionally mostly hinders the delivery of most therapeutic agents to the brain. Even the BBB is also partly noncontiguous because of the anemia

harm in later stages following stroke, the degree of outflow might not be adequate for delivery of serious quantities of medicine for effective stroke treatment, particularly the molecule compounds. Therefore, methods to extend neuro protectants uptake in cerebral anemia will not solely greatly ameliorate the therapeutic potency, however additionally contribute to their clinical translation. Besides, stem cells, a gaggle of cells with distinct proliferation and differentiation potential, that on paper can directly repair broken brain tissue, are thought of as a promising medical care for stroke treatment. Increasing proof shows that stem cells have neuro protecting effects on stroke animal models. And it has been found that blood obtained from juvenile mice will rejuvenate conjunction malleability and improve the psychological feature functions of aging brain. However, several queries square measure remaining to be elucidated before the employment of stem cells. Significantly, more studies have to be compelled to ascertain the precise cell sorts possibly to demonstrate success within the management of stroke and therefore the best means for the delivery of those cells. Besides, attention has to be paid on the prevalence of long aspect effects like neoplasm formation, among others. moreover, however these planted cells exert effects on the vasculature, encompassing neurons and interstitial tissue and therefore the inflammatory method, all stay to be elucidated [38,39].

#### Biodegradable polymeric NPs (PNPs)

Biodegradable polymeric NPs (PNPs) are adopted as potential carriers for drug delivery to the central nervous system because of its high biocompatibility, nontoxic byproducts within the body and smart sustained-release profiles. PNP materials will chiefly be divided into artificial perishable polymers and natural macromolecular systems. the previous includes poly (lactic acid) (PLA), poly (glycolic acid), poly (D, L-lactide-co-glycolide acid) (PLGA), polycaprolactone and polyethylene glycol (PEG) PLGA; and also, the latter consists of chitosan, polysaccharide, gelatin, starch and then on. In recent years, PNPs have been widely used as an alternative for delivery of oligo nucleotides, proteins and small-molecule medication for the treatment of ischemic stroke. Natural perishable polymer with smart biocompatibility, biodegradability and low toxicity, is additionally widely used as matrix for the preparation of nanomedicine for the management of AIS. for instance, brain-targeted chitosan NPs effectively transported an oversized neuro protective peptide, that may be a basic FGF and a little amide substance of caspase-3 z-DEVD-FMK, at the same time to the brain via transferrin-receptor-mediated transcytosis. Since chitosan has poor solubility in an solution at neutral pH scale, Ding., *et al.* applied O-carboxymethyl chitosan, a soluble chitosan by-product, to deliver acetyl-11-keto- $\beta$ -boswellic acid, a main active constituent

from *Boswellia serrata* organic compound, for the medical aid of cerebral ischemia-reperfusion injury. Gelatin NPs have conjointly been developed as nanocarriers for the management of AIS, during which osteopontin, associate endogenous protein that has neuroprotective effects, was the payload. Intranasal administration of the nanoformulation expeditiously reduced mean infarction volume and extended the therapeutic window to a minimum of 6 h post middle cerebral artery occlusion (MCAO) [40-46].

### Liposome

Liposomes are a unit one among the earliest forms of nanostructure developed for drug delivery and currently the most of these are used as nanocarriers in each clinic and clinical trials thanks to their sensible biocompatibility, biodegradability and low toxicity. nice progress has been created in analysis on liposome technology, from typical vesicles capable of trappings each hydrophilic and lipotropic medication to "second-generation liposomes", whose circulation time are often prolonged by modulating the lipid composition, size and charge of the sac, and "third-generation liposomes", of that liposomes with specific molecular surface modifications are able to do active targeting drug delivery. For the management of AIS, liposomes with extended circulation time area unit wide used. The prolonged circulation of liposomes is often achieved by decreasing the particle size (<100 nm), incorporating the lipid membrane with gangliosides like monosialoganglioside GM1 derived from bovine brain or by surface modification with PEG. PEGylated liposomes were shown to accumulate within the ischemic brain hemisphere at an early stage ischemia reperfusion. This accumulation is also thanks to the improved porosity and retention result, since several reports showed that the BBB within the ischemic hemisphere is part broken. PEGylated liposomes are changed to extend their active targeting delivery to the brain anemia region. for instance, PEGylated lipid NPs conjugated to Fas substance protein are showed to be able to by selection gift in brain ischemic region. exploitation this NP loaded with 3-n-butylphthalide for targeted medical aid of brain anemia, vital enhancements in brain injury and in neurologic deficit when anemia was achieved. Despite the benefits of liposomes, presently there's no liposome-based nanomedicine on the market within the clinic for the management of AIS. For the treatment of different diseases, it is detected that though encapsulating medicine in liposomes are loosely shown to enhance pharmacology and biodistribution, nevertheless no marketed liposomal therapeutic agents have exhibited associate degree overall survival profit once directly compared with the traditional parent drug. The liposomal instability, drug outflow, short targeting and drug unleash at the target web site may be the key causes of this development. Therefore, the event of a lot of opti-

um liposomal-based nanoplatform is additionally important for the bench-to-bed translation of anti-AIS nanomedicine [47].

### Other biocompatible nanoparticles

Though nucleoside showed probably neuroprotective result in many severe medical specialty disorders, it's short plasma half-life, moderate facet effects and unable to cross the BBB, in order that it's ne'er been utilized in the case of cerebral diseases. In a very recent study, Gaudinet and associates conjugated nucleoside to lipid squalene, the bioconjugate assembled as NPs (SQAd) to increase the circulation of this glycoside and provided neuroprotection in mouse stroke models. Following cerebral anemia, those animals receiving general administration of SQAd showed a big improvement in their medicine deficit score. alternative neuroprotective medicine may even be conjugated to the lipide squalene to make nanoassemblies, providing economical methods for the treatment of severe medical specialty diseases [48-51].

S. No	Patent No.	Active Ingredient	Excipients	References
1	US2014 0004186	Atorvastatin	K85EE, Tween 20, K85FA, PRB-, Lecithin	[52]
2	CA2639 921C	Tacrolimus	Argan Oil, Labrafil M 1944 CS, Ethanol	[53]
3	CN10227 4274 B	Pueraria flavonoid	Castor Oil, Cremophore, Propylene glycol	[54]
4	US201300 96196A1	Isotretinoin	Soyabean oil, Gelucire 50/13, Span 80	[55]
5	CN102319 302 B	TPG Glycoside	Oleate, polyoxyethylene 40 hydrogenated castor oil, glycol Monoethyl ether	[56]
6	CN10338 1138A	calcium salt of (3R, 5S, 6E)-7-[6-fluoro-4,7-diphenylsulfoquinolyl-3]yl-3,5-dihydroxy-6-heptenoic acid	Oleic acid, tween 80, PEG 400	[57]
7	US00848 6445B2	Mitotane	Propylene glycol monocaprylate, propylene glycol dicaprate, polyoxyethylenesorbitanne monooleate	

8	US00859 2490B2	Candesartan cilexetil, Celecoxib, Sirolimus	Polysorbate 80, Glyceryl caprylate, capric triglyceride	
9	WO20120 71043 A1	Mitotane	Polysorbate 80, Labrasol, Capryol 90	[58]
10	CN1018 62306 B	Vinpocetine	Miglyol, oleic acid, Cremo- phore EL, Trans- cutol P	[59]
11	CN1011 38549 B	Mitiglinide calcium	Oleate, Tween 85, Propylene glycol	[60]
12	WO20120 32415 A2	Atorvastatin	Polysorbate 20, polyoxyl 15 hy- droxystearate, sesame oil	[61]
13	US00825 2326B2	Coenzyme Q10	Isopropyl My- ristate, Lemon oil, Polysorbate 80, Span 80, Transcutol P	
14	EP24514 38 A2	Hepatitis C viral protease inhibi- tor	Capmul MCM, Cremophore EL, Propylene Glycol	[62]
15	CA7815 25 A1	Omega-3 ethyl ester fatty acid	Ethyl oleate, tween 20, K85EE, tween 80	[63]
16	CN1020 08471A	Lacidipine	Miglyol 812, Solutol HS15, Transcutol	[64]
17	CN1021 88373A	Pacitaxel	Miglycol 812N, Cremophore EL, Labrasol, Transcutol P	[65]
18	US20110 293714 A1	Derivatized in- sulin peptides	Propylene glycol, Labrasol, glycerol capry- late	[66]
19	EP2314 284 A2	Cannabinoids	Ethanol, Pro- pylene glycol, Cremophore RH40	[67]
20	CN1015 84661 B	Sorafenib	Oleate polyoxy- ethylene castor oil, ethanol, PEG400	[68]
21	WO2010 01043 A1	Curcumin	Gelucire, Labra- sol, Vitamin E TPGS	[69]

22	CA2754 860 A1	Omega-3 fatty acid	Solutol HS, Cremophore EL, Tween 20	[70]
23	CN1017 91290 A	Tetraacetyl puerarin	Propylene glycol laurate, Tween 80, ethylenegly- col Monoethyl ether	[71]
24	CN1019 12447 A	Xiatianwv total alkaloid extract	Oleic acid and Linolic acid, polyethylene glycol 15 stea- rate 4 hydroxyl dimethyl isosor- bide 30,6-tri- glyceride	[72]
25	US20100 266683 A1	Naproxen	Pluronic L127, sorbitanmono- laurat, propyl- ene glycol	[73]
26	US0077 36666B2	Naproxen	Pluronic L101®, sorbi- tanmonolaurat, ethanol	
27	WO2014 009434A1	Abiraterone	Captex 355/ Capmul MCM, Cremophore EL	[74]
28	CA257 8130C	Butylbenzene Phthalein	Polyoxyethylene castor oil, , poly- ethyleneglycol-8 glycerin capry- late, ethanol	[75]
29	CN1014 16954 A	Nitrendipidine	Linoleic acid, PEG 400, Etha- nol	[76]
30	EP2111 854 A1	Ketoprofen	Labrasol, Plurol Oleique, Migly- col 812	[77]
31	EP2127 642 A2	Testosterone Propionate	Miglycol 812, Brij 96, Ethanol	[78]
32	US20090 186926 A1	CETP inhibitors	Capmul PG8, Cremophore EL, Tween 80	[79]
33	WO2009 130225 A2	Celecoxib	Labrasol, Plurol oleique, Miglyol 812	[80]
34	CN1012 39039 A	Puerarin	Ethyl oleate, tween 80, PEG 400	[81]

35	WO2008 073731 A2	Valsartan	Lauroglycol, Propylene glycol, tween 20, Cremophore, Spearmint oil, PEG400, Labrafil M2125, Capmul, Maisine 35-1	[82]
36	EP196 1412A1	Candesartan cilexetil, celecoxib	Miglyol 812, Polysorbate 80, Imwitor 308	[83]
37	EP196 5764 A2	Torcetrapib	Imwitor 742, Miglyol 812, butylated hydroxyanisole, Vitamin E TPGS	[84]
38	WO2008 142090 A1	Tipronavir	PEG 400, Propylene glycol, Vitamin E Polyethylene glycol succinate, Capmul MCM.	[85]
39	US20070 298099 A1	N <sup>1</sup> -[3-[N <sup>2</sup> -(4chlorophenyl) 2(3cyanophenyl)1methylpropyl]2methyl2[[5-trifluoromethyl]pyridine2yl]oxy]propenamide	Imwitor 742, Polysorbate 80, Miglycol 812	[86]
40	US00722 6932B2	N <sup>1</sup> -[3-[N <sup>2</sup> -[[[(1,1-dimethylethyl)amino]carbonyl]-N <sup>2</sup> -(2-methylpropyl)amino]-2(R)-hydroxy-1(S)-(phenylmethyl)propyl]-2(S)-[N <sup>3</sup> -(2-quinolinylnylcarbonyl)amino]butanedi-amide	Polyethylene glycol 400, propylene glycol, ethanol and tween 80	
41	US20060 014788 A1	3[[[3(4-chloro3-ethyl phenoxy)phenyl] [3(1,1,2,2-tetrafluoroethoxy)phenyl] methyl] amino]1,1,1trifluoro 2propanol	Miglycol 812, triacetin, polysorbate 80, Campmul MCM	[87]

42	US20060 263397 A1	Simvastatin	Polysorbate 80 glycosperse O-20, propylene glycol, Transcutol P, Ethyl linoleate	[88]
43	US 2005/ 0232952 A1	Paclitaxel	Polyoxyl hydrogenated castor oil, vitamin E, Tyloxapol, D- $\alpha$ -tocopheryl polyethylene glycol succinate 1000, deoxycholic acid sodium salt and ethanol	[89]
44	CA254 9462 A1	(3R,3aS,6aR)~hexahydrofuro [2,3b]furan3yl (1S,2R)3[[[4aminophenyl] sulfonyl] (isobutyl) amino] 1benzyl 2hydroxy propylcarbamate	Caprylocaproyl macrogol-8-glyceride, lauryl macrogol-32-glyceride, purified Diethylene glycol Monoethyl ether	[90]
45	CN1682 701 A	Curcumin	Tween 80, ethanol, sunflower oil	[91]
46	EP260 0838 A2	6'fluoro(N,Ndimethyl)4phenyl4',9'dihydro3'Hspiro [cyclohexane 1,1'pyrano [3,4,b] indol]4amine	Gelucire 44/14, Labrasol, Capryol 90	[92]
47	US 2004/ 0048934 A1	N <sup>1</sup> -[3-[N <sup>2</sup> -[[[(1,1-dimethylethyl)amino]carbonyl]-N <sup>2</sup> -(2-methylpropyl)amino]-2(R)-hydroxy-1(S)-(phenylmethyl)propyl]-2(S)-[N <sup>3</sup> -(2-quinolinylnylcarbonyl)amino]butanedi-amide	Neobee oil, Tagat TO, ethanol	[93]
48	EP140 6598 A1	Halofantrine	Captex 355, Capmul MCM, Cremophore EL, Ethanol	[94]

49	EP148 0636 A2	Paclitaxel	Polyoxyl hydro- genated castor oil, propylene glycol, Vitamin E, TPGS	[95]
50	WO20 040024 14 A2	Fenofibrate	Transcutol P, Captex 200, Labrasol, Span 80	[96]
51	US655 5558 B2	Tipranavir	Capmul MCM, Cremophore EL, Propylene glycol	[97]
52	CA 245 5288 A1	[2R,4S] 4[(3,5bistri- fluoro methyl- benzyl)Me- thoxycarbonyl amino]2- ethyl6-trifluoro methyl3,4-di- hydro2-H quino- line1- carboxylic Acid ethyl ester	Polysorbate 80, Capmul MCM, Miglyol 812, Triacetin	[98]
53	CN145 7795 A	Kudzu flavonoid	Ethyl oleate, Tween 80, pro- pylene glycol	[99]
54	US 2002/01 19198 A1	3-[(2,4-dimeth- ylpyrrol-5-yl) methylene]- 2-indolinone		[100]
55	EP134 0497A1	Paclitaxel	Polyoxyl hydro- genated castor oil, vitamin E, D- $\alpha$ -tocopheryl polyethylene glycol succinate 1000, deoxycho- lic acid sodium salt and ethanol	[101]
56	WO 02/07 712 A2	Indolinone derivatives	Cremophore, Capmul MCM, Gelucire 44/14	[102]
57	CA237 7086 A1	o-(chloroa- cetylcar- bonyl) fumigillol	Tween 80, Cap- tex 200, Capmul MCM	[103]

**Table 3:** Recent patents filed with respect to the nanocrystals.

## Conclusion

Hereby, by this article we conclude to the vast application of the nanocarriers over the medical industry in the coming years. The field of nanocarriers is blooming with the various pharmacological applications and making its own way in elucidating that whether it is a boom or a bane in the upcoming years. In the coming years, due to the patient compliance and patient safety toward the adverse drug effect, the drug targeting and the drug efficacy in less dosing regimen would take a prior step clinically. This article takes you to a short journey of the production of different nanocarriers to their pharmacological applications and advancements expected in the same field.

## Bibliography

1. Carolan Darragh. "Recent advances in germanium nanocrystals: Synthesis, optical properties and applications". *Progress in Materials Science* 90 (2017): 128-158.
2. Åkerman E., *et al.* "Nanocrystal targeting in vivo". *Proceedings of the National Academy of Sciences of the United States of America* 99 (2002): 12617-12621.
3. Faraji H and Wipf P. "Nanoparticles in cellular drug delivery". *Bioorganic and Medicinal Chemistry* 17 (2009): 2950-2962.
4. Gener P., *et al.* "Cancer stem cells and personalized cancer nanomedicine". *Nanomedicine (Lond)* 11 (2016): 307-320.
5. Hillaireau H., *et al.* "Nanocarriers entry into the cell: relevance to drug delivery". *Cellular and Molecular Life Sciences* 66.17 (2009): 2873-2896.
6. Grishkewich N., *et al.* "Recent advances in the application of cellulose nanocrystals". *Current Opinion in Colloid and Interface Science* 29 (2017): 32-45.
7. Kwangjae C., *et al.* "Therapeutic Nanoparticles for Drug Delivery in Cancer". *Clinical Cancer Research* 14 (2008): 1310-1316.
8. Ventola CL. "Progress in Nanomedicine: Approved and Investigational Nanodrugs". *PT* 42 (2017): 742-55.
9. Nishiyama N and Kataoka K. "Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery". *Pharmacology and Therapeutics* 112 (2006): 630-648.
10. Daniel B., *et al.* "Optimization of the isolation of nanocrystals from microcrystalline cellulose by acid hydrolysis". *Journal of Biomaterials and Nanobiotechnology* 13 (2006): 171-180.
11. Yin Y and Paul AA. "Colloidal nanocrystal synthesis and the organic-inorganic interface". *Nature* 437.7059 (2005): 664-670.

12. Rainer HM and Cornelia MK. "Challenges and solutions for the delivery of biotech drugs – a review of drug nanocrystal technology and lipid nanoparticles". *Journal of Biotechnology* 113 (2004): 151-170.
13. Dwaine FE and Christopher GT. "The pinpoint promise of nanoparticle-based drug delivery and molecular diagnosis". *Biomolecular Engineering* 23 (2006): 171-84.
14. Tamizhrasi S., et al. "Formulation and Evaluation of Lamivudine Loaded Polymethacrylic Acid Nanoparticles". *International Journal of PharmTech Research CODEN ( USA)* 1 (2009): 411-415.
15. Dong Y., et al. "Recent Advances toward Practical Use of Halide Perovskite Nanocrystals". *Chemistry A* 122 (2018): 5235-5240.
16. Khlebtsov N and Dykman L. "Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies". *Chemical Society Reviews* 40 (2011): 1647-1671.
17. Kim J., et al. "Multifunctional Uniform Nanoparticles Composed of a Magnetite Nanocrystal Core and a Mesoporous Silica Shell for Magnetic Resonance and Fluorescence Imaging and for Drug Delivery". *Angewandte Chemie* 47 (2008): 8438-8441.
18. Santhoshkumar J., et al. "Phyto-assisted synthesis, characterization and applications of gold nanoparticles – A review". *Biochemistry and Biophysics Reports* 11 (2017): 46-57.
19. Torchilin VP. "Micellar Nanocarriers: Pharmaceutical Perspectives". *Pharmaceutical Research* 24 (2007): 1-10.
20. Kumar PR., et al. "Molecular and immunological toxic effects of nanoparticles". *International Journal of Biological Macromolecules* 107 (2018): 1278-1293.
21. Torchilin PV. "Multifunctional nanocarriers". *Advanced Drug Delivery Reviews* 64 (2012): 302-315.
22. Gi Y., et al. "Evaluation of Nanomedicine". *Springer* 1 (2014): 16-20.
23. Peer D., et al. "Nanocarriers as an emerging platform for cancer therapy". *Nature Nanotechnology* 2 (2007): 34-41.
24. Ringe E. "Nanocrystalline materials: recent advances in crystallographic characterization techniques". *IUCrj* 1 (2014): 530-539.
25. Gao J., et al. "Nanomedicine strategies for sustained, controlled and targeted treatment of cancer stem cells". *Nanomedicine* 11 (2016): 60.
26. Mishra B., et al. "Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery". *Nanomedicine: Nanotechnology, Biology, and Medicine* 6 (2010): 9-24.
27. Martins P., et al. "Nanoparticle Drug Delivery Systems: Recent Patents and Applications in Nanomedicine". 3 (2013): 105-118.
28. Merisko E and Liversidge GG. "Nanosizing for oral and parenteral drug delivery: A perspective on formulating poorly-water soluble compounds using wet media milling technology". *Advanced Drug Delivery Reviews* 63 (2011): 427-440.
29. Patravale VB., et al. "Nanosuspensions: a promising drug delivery strategy". *Journal of Pharmacy and Pharmacology* 56 (2004): 827-840.
30. Arora S., et al. "Nanotoxicology and in vitro studies: The need of the hour". *Toxicology and Applied Pharmacology* 258 (2012): 151-165.
31. Cafaggi S., et al. "Preparation and evaluation of nanoparticles made of chitosan or N-trimethyl chitosan and a cisplatin–alginate complex". *Journal of Controlled Release* 121 (2007): 110-123.
32. Mahadevu R., et al. "Recent advances in the preparation of nanocrystal solids". *Pramana Journal of Physics* 84 (2015): 1065-1071.
33. Rana S., et al. "On the suitability of nanocrystalline ferrites as a magnetic carrier for drug delivery: Functionalization, conjugation and drug release kinetics". *Acta Biomaterialia* 3 (2007): 233-242.
34. Mohanraj VJ and Chen Y. "Nanoparticles – A Review". *Tropical Journal of Pharmaceutical Research* 5 (2006): 65.
35. Bowman M., et al. "Reviewing the regulatory barriers for nanomedicine: global questions and challenges". *Nanomedicine (Lond)* 10 (2015): 3275-3286.
36. Sherlock PS., et al. "Photothermally Enhanced Drug Delivery by Ultrasmall Multifunctional FeCo/Graphitic Shell Nanocrystals". 5 (2011): 1505-1512.
37. Slowing II., et al. "Mesoporous Silica Nanoparticles for Drug Delivery and Biosensing Applications". *Advanced Functional Materials* 17 (2007): 1225-1236.
38. LaVan AD., et al. "Small-scale systems for in vivo drug delivery". *Nature Biotechnology* 21 (2003): 101-105.
39. Muller HR., et al. "Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art". *European Journal of Pharmaceutics and Biopharmaceutics* 50 (2000): 161-177.
40. Mura S., et al. "Stimuli-responsive nanocarriers for drug delivery". *Nature materials* 12 (2013): 154-159.

41. Chen L and Gao X. "The application of nanoparticles for neuroprotection in acute ischemic stroke". *Therapeutic Delivery* 8 (2017): 915-928.
42. Pierce LR. "Translational nanomedicine – through the therapeutic window". *Nanomedicine (Lond)* 10 (2015): 3249-3260.
43. Xie H., *et al.* "Recent Strategies in Preparation of Cellulose Nanocrystals and Cellulose Nanofibrils Derived from Raw Cellulose Materials". *International Journal of Polymer Science* 5 (2018): 125.
44. Chen Q., *et al.* "All-inorganic perovskite nanocrystal scintillators". *Nature* 561 (2018): 88-93.
45. Scalise E., *et al.* "Surface chemistry and buried interfaces in all-inorganic nanocrystalline solids". *Nature Nanotechnology* 13 (2018): 841-848.
46. Tahara H., *et al.* "Quantum coherence of multiple excitons governs absorption cross-sections of PbS/CdS core/shell nanocrystals". *Nature Communications* 9 (2018): 3179.
47. Hanson AL., *et al.* "Pseudoelasticity at Large Strains in Au Nanocrystals". *Physical Review Letters* 121 (2018): 056102.
48. Maudens P., *et al.* "Nanocrystal–Polymer Particles: Extended Delivery Carriers for Osteoarthritis Treatment". *Small* 14 (2018).
49. Berestok T., *et al.* "Surface chemistry and nano/microstructure engineering on photocatalytic In<sub>2</sub>S<sub>3</sub> nanocrystals". *Chemical Review* 116 (2016): 14056-14119.
50. Kagan RC. "Flexible colloidal nanocrystal electronics". *The Royal Society of Chemistry* (2018).
51. Pietryga MJ., *et al.* "Spectroscopic and Device Aspects of Nanocrystal Quantum Dots". *Chemical Review* 116 (2016): 10513-10622.
52. Hustvedt SO., *et al.* "Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form, a surfactant, and a statin". US20140004186A1. United States (2011).
53. Benita S., *et al.* "Microspheres comprising nanocapsules containing a lipophilic drug". CA2639921C. Canada (2007).
54. Self-microemulsifiable kudzu root flavone oral micro-pill composition and preparation method thereof". CN102274274B. China (2011).
55. Vanderbist F., *et al.* "Pharmaceutical semi-solid composition of isotretinoin. US20130096196A1 2013. United States.
56. Total paeony glucoside self-microemulsifying soft capsules and preparation method thereof. CN102319302 B. China (2011).
57. Statin oral self-microemulsifying release preparation and preparation method thereof. CN103381138A China (2012).
58. Van Bommel J., *et al.* "Media playing device". WO201207104 (2011).
59. New type slightly soluble oral medicine self-emulsification preparation and preparation method thereof. CN101862306 B. China (2009).
60. Mitiglinide calcium self-micro emulsifying drug delivery system. CN101138549 B. China (2007).
61. Berge G., *et al.* "Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form, a surfactant, and a statin. WO2012032415 A2 (2011).
62. Chen FJ., *et al.* "Pharmaceutical composition for a hepatitis c viral protease inhibitor". EP2451438 A2 (2014).
63. Harold RL., *et al.* "Lead titanate zirconate ceramic composition with additives". CA781525 A1. (1968).
64. Lacidipine self-micro emulsifying soft capsules and preparation method thereof. CN102008471A. China (2010).
65. Supersaturated self-microemulsified administration system for insoluble anti-tumor drugs, and preparation method thereof. CN102188373A. China (2010).
66. Föger FA. Pharmaceutical compositions suitable for oral administration of derivatized insulin peptides. US20110293714 A1. United States (2009).
67. Whittle BA. Cannabinoid liquid formulations for mucosal administration. EP2314284 A2 2009.
68. Preparation of sorafenib self-microemulsifying drug delivery system for oral administration or intravenous injection and use thereof. CN101584661 B. China (2009).
69. Marduel J. "Device and method for impregnating a porous material with powder". WO201001043 A1 (2010).
70. Hustvedt SO., *et al.* "Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof. CA2754860 A1. Canada (2010).
71. Tetra-acetylated puerarin self-micro emulsifying medication delivery system and preparation method thereof. CN101791290 A. China (2010).
72. Rhizoma corydalis total alkaloids self-emulsifying drug delivery system and preparation method and application thereof. CN101912447 A China (2010).
73. Holmberg C and Siekmann B. "New self emulsifying drug delivery system. US20100266683 A1 United States (2010).

74. Legen I, *et al.* "Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate". WO2014009434A1 (2013).
75. Liu Z, *et al.* "Butylbenzene phthalein self-emulsifying drug delivery system, its preparation method and application. CA2578130C. Canada (2007).
76. Nitrendipine self-emulsification soft capsules and preparation method thereof. CN101416954 A China (2008).
77. Gasperlin M, *et al.* "Self-microemulsifying systems incorporated into liquid core microcapsules". EP2111854 A1 (2009).
78. Pather IS, *et al.* "Microemulsions as solid dosage forms for oral administration". EP2127642 A2 (2009).
79. Sheth AR, *et al.* "Self-Emulsifying Formulations of CETP Inhibitors". US20090186926 A1. United States (2006).
80. Kerc J, *et al.* "Self-microemulsifying systems incorporated into liquid core microcapsules". WO2009130225 A2 (2009).
81. Establishing and evaluating method of self-emulsifying drug administration system common formula system. CN101239039 A. China (2008).
82. Joshi Y, *et al.* "Microemulsion dosage forms of valsartan and methods of making the same. WO2008073731 A2 (2007).
83. Legen I, *et al.* "Self-microemulsifying drug delivery systems". EP1961412A1 (2007).
84. Sheth AR, *et al.* "Self-Emulsifying Formulations of CETP Inhibitors". EP1965764 A2 (2006).
85. Abelaira S, *et al.* "Self-emulsifying formulation of tipranavir for oral administration". WO2008142090 A1 (2008).
86. Peresykin A, *et al.* "Liquid and Semi-Solid Pharmaceutical Formulations for Oral Administration of a Substituted Amide". US20070298099 A1 (2007).
87. Gumkowski M, *et al.* "Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors". US20060014788 A1. United States (2005).
88. Li W, *et al.* "Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same. US20060263397 A1. United States (2008).
89. Lambert G, *et al.* "Self emulsifying drug delivery systems for poorly soluble drugs". US 2005/0232952 A1. United States (2003).
90. Voorspoels JFM. "Self-microemulsifying drug delivery systems of a hiv protease inhibitor". CA2549462 A1. Canada (2004).
91. Self microemulsifying preparation of curcumin and its preparing process. CN1682701 A (2005).
92. Grüning N and Schiller M. "Pharmaceutical dosage form comprising 6'-fluoro- (n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine. EP2600838 A2 2013.
93. Gokhale R, *et al.* "Self-emulsifying drug delivery system. US 2004/0048934 A1. United States (2003).
94. Charman WN and Porter CJH. "Lymphatic drug delivery system". EP1406598 A1 (2001).
95. Benita S, *et al.* "Self emulsifying drug delivery systems for poorly soluble drugs". EP1480636 A2 (2003).
96. Hermansson L and Engqvist H. "Powdered material, method of manufacturing it, raw compact of the powdered material and device for the powdered material". WO200400241 (2003).
97. Shirlynn C and Jocelyn AG. "Oral dosage self-emulsifying formulations of pyranone protease inhibitors. US655558B2. United States (2000).
98. Michael J, *et al.* "Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors". CA2455288A1 2003. Canada.
99. Pueraria flavone self-microemulsifying soft capsule and preparation method thereof. CN1457795A. China (2009).
100. Ping G, *et al.* "Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs". US20020119198A1 2002. United States.
101. Simon B, *et al.* "Self emulsifying drug delivery systems for poorly soluble drugs". EP1340497A1. Europe (2003).
102. Ping G, *et al.* "Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs". WO2002007712A2. United States (2002).
103. Rong L and Zheng W. "Self-emulsifying systems containing anticancer medicament". CA2377086A1. Canada (2001).

**Volume 3 Issue 5 May 2019**

© All rights are reserved by Govind Arora, *et al.*